Fatima C.
- Country
- Portugal
- Department
- #2202: Unidade de Mama
Research Overview
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer
- Phase 2 Randomized Study of Camizestrant vs. Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer
Data & Insights
Has run more than one trial at 4 of 57 partner sites.
Specializations
Advanced Breast Cancer Treatment
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative advanced breast cancer, exploring innovative therapeutic combinations with targeted agents. Their research encompasses the evaluation of novel treatments including alpelisib and camizestrant in combination with established therapies.
- Endocrine therapy resistance mechanisms
- CDK4/6 inhibitor treatments
- Selective estrogen receptor degraders
Triple Negative Breast Cancer
The investigator focuses on developing treatments for triple-negative breast cancer, with particular emphasis on immunotherapy approaches. Their work includes studying immune system activation patterns and evaluating novel combination therapies including pembrolizumab.
- Immune system activation markers
- Neoadjuvant therapy responses
- TIL-positive disease management
Early-Stage Breast Cancer
Research interests include the treatment of early-stage breast cancer, particularly focusing on adjuvant therapy optimization. The investigator studies various therapeutic approaches including PARP inhibitors and novel endocrine treatments for hormone receptor-positive disease.
- BRCA-mutated breast cancer
- Adjuvant endocrine therapy
- Disease-free survival optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.